Mylan Announces Appointment of John Montgomery as President, As...( PITTSBURGH Oct. 2 /- Mylan Inc. (...),Health

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of John Montgomery to the position of President, Asia Pacific following the completion of Mylan's acquisition of Merck's Generics Group today.

Mr. Montgomery has worked for over 30 years in the pharmaceuticals industry and has extensive experience in both patented and generics pharmaceutical products in the UK, U.S. and Asia Pacific regions. At Merck Generics, he served as Regional Director, Asia Pacific, and CEO of Alphapharm, Merck Generic's business in Australia and the country's leading pharmaceutical company as measured by prescriptions. Prior to joining Merck, he spent 18 years with Warner Lambert in the UK, U.S. and Australia in roles including Business Director, Europe; Vice President, Cardiovascular; Vice President of Portfolio Management for North America; and Regional President Australia/New Zealand. He served five years as Chairman of the Generic Medicines Industry Association (GMiA) in Australia.

Mylan Vice Chairman and CEO Robert J. Coury commented: "I have seen first hand that John is a truly skilled leader with the vision that makes him a perfect fit for Mylan. He brings an impressive track record and true depth of experience to our senior team. Asia Pacific is an important region with an attractive growth profile, particularly in Japan. Under John's leadership, his business ranks number one in both Australia and New Zealand, and also ranks as the leading multinational generics company in Japan. I am confident that we are extremely well-placed to leverage the many opportunities we see in the region from our position as a new global leader in the generics and specialty pharmaceutical industry."
'/>"/>